Ewopharma and CStone enter into a Strategic Partnership for Sugemalimab in Central Eastern Europe and Switzerland
Ewopharma announces today that it has entered into a strategic commercial collaboration with CStone Pharmaceuticals (“CS…
Ewopharma announces today that it has entered into a strategic commercial collaboration with CStone Pharmaceuticals (“CS…
Mindpeak, European leader in Artificial Intelligence in Pathology, today announced the launch of a new CE marked deep le…
Dose escalation for cell therapy candidate ACTengine® IMA203 ongoing; dose level 3 completed at doses below 1 billio…
Immatics’ first TCR Bispecific program IMA401 delivers preclinical proof-of-concept demonstrating complete remissions of…
First HER2 directed therapy to show an improvement in overall survival for previously-treated metastatic gastric cancer…
9% of patients with HER2 mutant metastatic non-small cell lung cancer treated with ENHERTU achieved a tumor response Bre…
Results from the phase 2 DESTINY-CRC01 trial of Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) and AstraZe…
• QIAGEN and Amgen to develop tissue-based therascreen® test, paired with investigational treatment AMG 510, to identify…
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that the Japanese Pharmaceuticals and Medical De…
NOXXON Pharma N.V. (Euronext Growth Paris: ALNOX), the "Company", a biotechnology company focused on improving cancer tr…